Vir Biotech gets FDA IND clearance & Fast Track for hepatitis delta combo therapy

Vir Biotechnology, Inc.

FDA cleared IND and granted Fast Track for tobevibart + elebsiran for chronic hepatitis delta.
Phase 2 SOLSTICE 24-week data expected Q4 2024; preliminary data showed high virologic response.
Company plans ECLIPSE trial to support potential registration, comparing combo to standard of care.
CEO Marianne De Backer says IND clearance underscores potential to transform treatment landscape.
Hepatitis delta affects at least 12 million people globally; considered most severe viral hepatitis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.